Jack Shuang Hou: Bayer Advances Asundexian as EMA Reviews New Option for Preventing Recurrent Ischemic Stroke
Jack Shuang Hou, Diagnostic Executive, Microfluidics and Immunoassay Specialist, shared on LinkedIn:
”Bayer Advances Asundexian as European Medicines Agency (EMA) Begins Review for Secondary Prevention of Ischemic Stroke
Bayer announced that the European Medicines Agency (EMA) has validated and started reviewing the Marketing Authorization Application for Asundexian, its investigational oral Factor XIa (FXIa) inhibitor, for prevention of recurrent ischemic stroke in adults following a non-cardioembolic ischemic stroke or high-risk transient ischemic attack (TIA).
This marks the first regulatory review of a Factor XIa inhibitor in Europe and follows positive Phase 3 OCEANIC-STROKE results.
Why this matters
Potential first-in-class FXIa inhibitor enters European review
- Targets secondary prevention of ischemic stroke
- Oral once-daily Factor XIa inhibitor
- First FXIa inhibitor submitted for marketing authorization in Europe
- Designed to reduce thrombotic events while minimizing bleeding risk
FXIa inhibition represents a novel anticoagulation strategy aimed at separating thrombosis prevention from normal hemostasis.
Positive Phase 3 OCEANIC-STROKE results support filing
- 12,327 patients enrolled globally
- 26 percent reduction in recurrent ischemic stroke versus placebo
- No increase in ISTH major bleeding
- Studied in combination with standard antiplatelet therapy
The pivotal trial evaluated asundexian in patients following non-cardioembolic ischemic stroke or high-risk TIA, addressing a major unmet need in stroke prevention.
Significant public health opportunity
Stroke remains the second leading cause of death globally and across Europe
- Approximately 10 million Europeans live with stroke-related disability
- More than 1 million new stroke cases occur annually in Europe
- Global stroke-related costs are estimated at nearly $891 billion annually
As stroke prevalence and mortality continue to rise, new treatment options that improve outcomes without increasing bleeding risk could have substantial clinical impact.
Leadership Perspective
Christian Rommel, Global Head of Research and Development, Bayer | Pharmaceuticals, highlighted the growing burden of ischemic stroke across Europe and emphasized that EMA acceptance of the application reflects
My takeaway
Asundexian is emerging as one of the most closely watched cardiovascular pipeline assets in the industry. The combination of a 26% stroke reduction and no significant increase in major bleeding suggests FXIa inhibition may represent a meaningful advance beyond current antithrombotic strategies. If approved, asundexian could help establish an entirely new class of stroke prevention therapies.”
Stay updated with Hemostasis Today.
-
Sep 18, 2026, 14:33Heghine Khachatryan: The discussion of Thrombophilia, APS and Coagulation Testing
-
Sep 18, 2026, 14:27Maria Cherska: Are We Overlooking the Spleen in Cardiometabolic Research?
-
Sep 18, 2026, 14:05Wolfram Ruf: Managing Thrombotic Risk in Pregnancy
-
Sep 18, 2026, 13:38Sam Tsimikas: Uncovering a Modifiable Lp(a) Phenotype in Hypertriglyceridemia
-
Sep 18, 2026, 13:22Christine Rabinak: Predictive Modeling for Individualized Unfractionated Heparin Dosing
-
Sep 18, 2026, 13:07Bastu Odoka: Principles of Pediatric Transfusion Dosing
-
Sep 18, 2026, 12:54David McIntosh: Plasma Therapies and the Unfinished Global Access Mission
-
Sep 18, 2026, 11:10R. Stephani Hellwege: Beyond LVEF Echocardiographic Assessment of Undifferentiated Shock
-
Sep 18, 2026, 06:48Gopal Patidar: Honoured to Contribute to the ASFA 2026 Guidelines for Therapeutic Apheresis